- Home
- EPSM vs QNCX Comparison
EPSM vs QNCX Comparison
Compare EPSM & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | QNCX |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | China | United States |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 19.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EPSM | QNCX |
|---|---|---|
| Price | $1.06 | $1.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 75.6K | ★ 1.4M |
| Earning Date | 04-29-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.08 |
| 52 Week High | $155.00 | $4.55 |
Technical Indicators
Market Signals| Indicator | EPSM | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 46.14 |
| Support Level | N/A | $0.79 |
| Resistance Level | $1.49 | $1.45 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 27.42 | 44.64 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.